The GLP-1 analog liraglutide, a modified human GLP-1(737) with a longer half-life 29 , is administered systemically in patients with type II diabetes (commercial name Victoza ) and obesity (commercial name Saxenda )
[1] The most frequently reported adverse effects of semaglutide include gastrointestinal symptoms such as nausea, vomiting, diarrhoea, constipation, and abdominal pain
For example, your recent A1c level(s) and any additional lab results or notes from past doctors appointments
While not specifically a heartburn predictor, genetic variants affecting GLP-1 receptor sensitivity may influence overall GLP-1 side effect tolerance, helping personalize your starting dose and protocol
Key takeaways about weight loss drugs and low blood sugar GLP-1 and GIP receptor agonists are used on and off label to help people lose weight and manage type 2 diabetes
A healthcare provider reviews history, current drugs, and screens for weight related health condition risks like cardiovascular disease, heart failure, or certain cancers